Phase 3 Readout
RANI: Phase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor
October 1, 2032. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2032
- Company
- Rani Therapeutics Holdings, Inc. (RANI)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor
- Indication
- Breast Cancer